Atorvastatin (Ran-atorvastatin)
Atorvastatin
Ranbaxy (SA) (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Ranbaxy (SA) (Pty) Ltd
- Registrations
- 4
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ran-atorvastatin 10 EACH TABLET CONTAINS ATORVASTATIN 10,0 mg | 10 | 42054842/7.5/0548 | Cancelled | Not determined | None |
| Ran-atorvastatin 20 EACH TABLET CONTAINS ATORVASTATIN 20,0 mg | 20 | 42054942/7.5/0549 | Cancelled | Not determined | None |
| Ran-atorvastatin 40 EACH TABLET CONTAINS ATORVASTATIN 40,0 mg | 40 | 42055042/7.5/0550 | Cancelled | Not determined | None |
| Ran-atorvastatin 80 EACH TABLET CONTAINS ATORVASTATIN 80,0 mg | 80 | 42055142/7.5/0551 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Atorvastatin
Consolidated Schedules 06 July 2026, line 5376
S4: Ezetimibe
Consolidated Schedules 06 July 2026, line 6302
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
Drag to rotate. Structure from PubChem CID 60823.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.